Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.36 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82191 | 0.84 | HRH3 (0.51) | HRH3HDAC1MAP4K4HRH4SOS1 | |
| SCHEMBL82190 | 0.79 | MAP4K4 (0.47) | HRH3HDAC1MAP4K4HRH4SOS1 | |
| SCHEMBL19035556 | 0.78 | HRH3 (0.51) | HRH3HDAC1MAP4K4ROCK2ROCK1 | |
| SCHEMBL23263993 | 0.77 | MAP4K4 (0.51) | HRH3HDAC1MAP4K4HRH4 | |
| SCHEMBL30294197 | 0.77 | MAP4K4 (0.51) | HRH3HDAC1MAP4K4HRH4 | |
| SCHEMBL2324509 | 0.74 | HRH3 (0.47) | HRH3HDAC1MAP4K4HRH4ROCK2 | |
| SCHEMBL421586 | 0.74 | CHRNB2 (0.41) | LMNA | |
| SCHEMBL14161712 | 0.74 | MAP4K4 (0.47) | HRH3MAP4K4ROCK2ROCK1CDC42BPA | |
| SCHEMBL4127851 | 0.73 | HRH3 (0.37) | HRH3 | |
| SCHEMBL1779679 | 0.72 | HRH3 (0.45) | HRH3HDAC1MAP4K4HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | HRH3 1/4885HDAC1 471/4885MAP4K4 1444/4885 |
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | HRH3 1/4885HDAC1 471/4885MAP4K4 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.